Holen Sie sich die Stockscreener-App
7.78
0.39%
0.03
Handel nachbörslich:
7.78
Schlusskurs vom Vortag:
$7.75
Offen:
$7.69
24-Stunden-Volumen:
1.57M
Relative Volume:
1.47
Marktkapitalisierung:
$2.41B
Einnahmen:
$2.68B
Nettoeinkommen (Verlust:
$-184.45M
KGV:
-389.00
EPS:
-0.02
Netto-Cashflow:
$229.23M
1W Leistung:
-0.64%
1M Leistung:
-7.49%
6M Leistung:
+15.26%
1J Leistung:
+47.07%
1-Tages-Spanne:
$7.57
$7.86
1-Wochen-Bereich:
$7.57
$8.18
52-Wochen-Spanne:
$5.01
$9.475
Amneal Pharmaceuticals Inc Stock (AMRX) Company Profile
Firmenname
Amneal Pharmaceuticals Inc
Sektor
Telefon
908-947-3120
Adresse
400 Crossing Boulevard, 3rd Floor, Bridgewater
Vergleichen Sie AMRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AMRX
Amneal Pharmaceuticals Inc
|
7.78 | 2.41B | 2.68B | -184.45M | 229.23M | -0.6805 |
|
ZTS
Zoetis Inc
|
164.84 | 74.37B | 9.15B | 2.43B | 2.31B | 5.32 |
|
HLN
Haleon Plc Adr
|
9.69 | 43.81B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.10 | 41.53B | 30.27B | 1.93B | 3.45B | 0.6044 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
22.09 | 25.03B | 16.77B | -959.00M | 1.37B | -0.85 |
|
VTRS
Viatris Inc
|
12.52 | 14.94B | 15.05B | -883.30M | 1.89B | -0.74 |
Amneal Pharmaceuticals Inc Stock (AMRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-09-06 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Sector Perform |
| 2021-03-08 | Hochstufung | Goldman | Sell → Buy |
| 2020-12-14 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2020-12-14 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-07-27 | Eingeleitet | Goldman | Sell |
| 2020-05-12 | Hochstufung | Guggenheim | Sell → Neutral |
| 2019-12-12 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2019-11-12 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2019-11-07 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2019-07-22 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2019-07-11 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-07-08 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2019-06-11 | Eingeleitet | Barclays | Equal Weight |
| 2019-05-21 | Hochstufung | Raymond James | Mkt Perform → Strong Buy |
| 2019-03-20 | Eingeleitet | SunTrust | Buy |
| 2019-03-08 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2018-12-14 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2018-10-16 | Herabstufung | SunTrust | Buy → Hold |
| 2018-08-13 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-07-23 | Eingeleitet | Morgan Stanley | Overweight |
| 2018-06-22 | Eingeleitet | B. Riley FBR, Inc. | Buy |
Alle ansehen
Amneal Pharmaceuticals Inc Aktie (AMRX) Neueste Nachrichten
Wellington Management Group LLP Buys Shares of 82,596 Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - MarketBeat
Teva loses US appeal to keep inhaler patents on FDA protected drug list - Reuters.com
Amneal Pharmaceuticals (NASDAQ:AMRX) Rating Lowered to "Buy" at StockNews.com - MarketBeat
Amneal Pharmaceuticals (NASDAQ:AMRX) Stock Price Up 4.5%Here's What Happened - MarketBeat
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Receives $10.00 Average Price Target from Analysts - MarketBeat
BNP Paribas Financial Markets Sells 402,852 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - MarketBeat
Amneal Pharmaceuticals' SWOT analysis: generic drug maker's stock poised for growth - Investing.com
Parkinson's Disease Market to Reach New Heights in Growth - openPR
SERD Therapeutics Market Key Players AnalysisAmneal - openPR
Epinephrine Autoinjector Market to Grow by USD 2.44 Billion (2024-2028), Driven by Rising Allergy Prevalence and AI-Powered Market TransformationTechnavio - The Malaysian Reserve
Jacobs Levy Equity Management Inc. Sells 189,881 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - MarketBeat
Charles Schwab Investment Management Inc. Buys 202,863 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - MarketBeat
Walleye Capital LLC Invests $1.10 Million in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - MarketBeat
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Shares Purchased by Polar Asset Management Partners Inc. - MarketBeat
Amneal to Participate at Upcoming Investor Conferences - BioSpace
Amneal Pharmaceuticals Leadership to Present at Major Healthcare Investment Conferences - StockTitan
Quantbot Technologies LP Grows Stock Holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - MarketBeat
Amneal Pharmaceuticals director John Kiely sells $142,946 in stock By Investing.com - Investing.com Australia
Amneal Pharmaceuticals director John Kiely sells $142,946 in stock - Investing.com India
Insider Sell: Deborah Autor Sells 40,000 Shares of Amneal Pharma - GuruFocus.com
Glioblastoma Multiforme Treatment Market Size to Reach USD 5.68 Bn by 2033 - GlobeNewswire Inc.
Amneal Set To Debut US Byetta Competition – Two Decades After Market Entry - Citeline
Premature Ejaculation Treatment Market to Grow by USD 1.46 Billion (2024-2028), Boosted by Effective Off-Label Drugs, Market Evolution Powered by AITechnavio - The Malaysian Reserve
Amneal Pharmaceuticals exec sells shares worth $114,786 - Investing.com India
Amneal Pharmaceuticals exec sells shares worth $114,786 By Investing.com - Investing.com Nigeria
Amneal gets FDA approval for generic Byetta, resubmits DHE NDA - MSN
Amneal files again for FDA approval of first dihydroergotamine autoinjector - Pharmaceutical Technology
Amneal resubmits migraine autoinjector NDA, receives FDA nod for exenatide By Investing.com - Investing.com Canada
Amneal Resubmits DHE Autoinjector New Drug Application and Receives U.S. FDA Approval of Exenatide, its First Generic Injectable GLP-1 Agonist - BioSpace
Amneal Resubmits New Drug Application for Migraine Treatment, Diabetes Drug Is Approved - MarketWatch
Amneal resubmits migraine autoinjector NDA, receives FDA nod for exenatide - Investing.com India
GSA Capital Partners LLP Has $452,000 Stock Holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - MarketBeat
Senior VP Of Amneal Pharmaceuticals Sold 76% Of Their Shares - Simply Wall St
Amneal Pharmaceuticals Q3 2024 Earnings Preview - MSN
AMNEAL PHARMACEUTICALS, INC. (AMRX) Hit a 52 Week High, Can the Run Continue? - MSN
Brokerages Set Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Price Target at $10.00 - MarketBeat
Phocas Financial Corp. Reduces Position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - MarketBeat
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Short Interest Down 16.3% in October - MarketBeat
Sandoz, Amneal Get Mixed Ruling in State Drug Price-Fixing Case - Bloomberg Law
Amneal stock target gets a boost, overweight on strong Q3 results - Investing.com Canada
Amneal Pharmaceuticals (NASDAQ:AMRX) Hits New 1-Year High After Analyst Upgrade - MarketBeat
Piper Sandler Raises Amneal Pharmaceuticals (NASDAQ:AMRX) Price Target to $11.00 - MarketBeat
AMRX Stock Soars to 52-Week High, Reaching $8.97 Amid Growth - Investing.com
Revenues Working Against Amneal Pharmaceuticals, Inc.'s (NASDAQ:AMRX) Share Price - Simply Wall St
Amneal Pharmaceuticals Inc (AMRX) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ... By GuruFocus - Investing.com Canada
Earnings call: Amneal Pharmaceuticals sees a 13% revenue surge in Q3 2024 - Investing.com
Amneal Delivers On Biosimilars Ambitions With Neupogen Rival - Citeline News & Insights
Amneal Pharmaceuticals (AMRX) Surpasses Q3 Earnings and Revenue Estimates - MSN
Amneal Pharmaceuticals, Inc. (NYSE:AMRX) Q3 2024 Earnings Call Transcript - MSN
Finanzdaten der Amneal Pharmaceuticals Inc-Aktie (AMRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.61%
1.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):